Continuing intrathecal immunoactivation despite two years of effective antiretroviral therapy against HIV-1 infection

scientific article published in November 2002

Continuing intrathecal immunoactivation despite two years of effective antiretroviral therapy against HIV-1 infection is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1097/00002030-200211080-00006
P698PubMed publication ID12409735

P50authorDietmar FuchsQ38801487
Lars HagbergQ97650293
Bo SvennerholmQ124366846
P2093author name stringMagnus Gisslén
Sahra Abdulle
P433issue16
P407language of work or nameEnglishQ1860
P921main subjectanti-retroviral agentQ50430310
P304page(s)2145-2149
P577publication date2002-11-01
P1433published inAIDSQ4651863
P1476titleContinuing intrathecal immunoactivation despite two years of effective antiretroviral therapy against HIV-1 infection
P478volume16

Reverse relations

cites work (P2860)
Q37066982Antiretroviral therapy and central nervous system HIV type 1 infection
Q37073672Biomarkers of HIV related central nervous system disease
Q41070059Blood brain barrier impairment is associated with cerebrospinal fluid markers of neuronal damage in HIV-positive patients
Q38597765CNS reservoirs for HIV: implications for eradication
Q47894419CSF inflammatory markers and neurocognitive function after addition of maraviroc to monotherapy darunavir/ritonavir in stable HIV patients: the CINAMMON study
Q24814874Cerebrospinal fluid HIV infection and pleocytosis: relation to systemic infection and antiretroviral treatment
Q33237758Cerebrospinal fluid HIV-1 RNA, intrathecal immunoactivation, and drug concentrations after treatment with a combination of saquinavir, nelfinavir, and two nucleoside analogues: the M61022 study
Q82029827Cerebrospinal fluid markers in central nervous system HIV infection and AIDS dementia complex
Q36854127Cerebrospinal fluid neopterin decay characteristics after initiation of antiretroviral therapy
Q33933507Cerebrospinal fluid neopterin: an informative biomarker of central nervous system immune activation in HIV-1 infection
Q38551796Compartmentalized intrathecal immunoglobulin synthesis during HIV infection - a model of chronic CNS inflammation?
Q37015519Defining and evaluating HIV-related neurodegenerative disease and its treatment targets: a combinatorial approach to use of cerebrospinal fluid molecular biomarkers
Q99713341Effect of Opioid Use on Immune Activation and HIV Persistence on ART
Q46812278Immune activation of the central nervous system is still present after >4 years of effective highly active antiretroviral therapy
Q34699119Impact of antiretroviral therapy on HIV-related brain injury
Q88753335Improved Cognitive Performance and Reduced Monocyte Activation in Virally Suppressed Chronic HIV After Dual CCR2 and CCR5 Antagonism
Q36250020Loss of CCR2 expressing non-classical monocytes are associated with cognitive impairment in antiretroviral therapy-naïve HIV-infected Thais
Q35052651Minocycline fails to modulate cerebrospinal fluid HIV infection or immune activation in chronic untreated HIV-1 infection: results of a pilot study
Q35154529Monocytes mediate HIV neuropathogenesis: mechanisms that contribute to HIV associated neurocognitive disorders
Q38575775Neopterin in Diagnosis and Monitoring of Infectious Diseases
Q37089861NeuroAIDS: characteristics and diagnosis of the neurological complications of AIDS.
Q33257724Normalisation of cerebrospinal fluid biomarkers parallels improvement of neurological symptoms following HAART in HIV dementia--case report
Q37066971Persistent intrathecal immune activation in HIV-1-infected individuals on antiretroviral therapy
Q38247035Pharmacokinetics and pharmacodynamics of antiretrovirals in the central nervous system
Q42208551Prevalence and predictors of blood-brain barrier damage in the HAART era.
Q34678105Progressive increase in central nervous system immune activation in untreated primary HIV-1 infection
Q46820459Temporarily controlled HIV-1 replication after intravenous immunoglobulin treatment of Guillain-Barré syndrome.
Q34718135Treatment intensification with maraviroc (CCR5 antagonist) leads to declines in CD16-expressing monocytes in cART-suppressed chronic HIV-infected subjects and is associated with improvements in neurocognitive test performance: implications for HIV-a
Q37372353Tryptophan Metabolism and Its Relationship with Depression and Cognitive Impairment Among HIV-infected Individuals

Search more.